Renovia, a digital therapeutics maker for female pelvic floor disorders, today shared the closing of its Series C-1 financing round worth $17 million.
The round included previous backers including Perceptive Life Sciences, Longwood Fund, Ascension Ventures and OSF Ventures, in addition to new investor Parian Global Management.
WHAT THEY DO
Renovia's flagship product, leva, is an FDA-cleared...
It’s been two years since the first software-only digital therapeutic got the FDA greenlight, but the industry is still very much in its infancy and continuing to evolve. New entrances are emerging from the world of health, pharma, tech and finance. As the industry matures, it's grappling with existential questions including regulation, reimbursement models and, as always, the definition of a...
